Embolic Stroke Clinical Trial
Official title:
A Random, Double-blind, Parallel, Placebo-controlled, Multi-center Study of Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism
This is a randomized, double blind, placebo-controlled, parallel, multicenter research in
order to evaluate the effect of Shuxuetong injection in prevention of symptomatic or
asymptomatic new cerebral infarction within 10 days.
Subgroup study：Evaluate the role of advanced diagnostic technique in identifying potential
causes of Embolic Stroke of Undetermined Source (ESUS).
Shuxuetong injection or Placebo injection for 10days. About 2416 patients randomized at 80
centers all over China with 20 subgroup study centers.
Face to face interview at baseline, 10 days, and 90 days.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04559243 -
Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events
|
||
| Completed |
NCT02759653 -
Norwegian Carotid Plaque Study
|
||
| Recruiting |
NCT03543319 -
Norwegian Microemboli in Acute Stroke Study
|
||
| Completed |
NCT02185885 -
Perfusion Pressure Cerebral Infarction Trial (PPCI)
|
N/A | |
| Recruiting |
NCT05558774 -
Long-term Outcomes After Percutaneous Closure of PFO
|
||
| Not yet recruiting |
NCT02224131 -
Study of Antiplatelet Therapy for Intracranial Aneurysm Stent-assisted Coiling
|
Phase 4 | |
| Unknown status |
NCT02159287 -
Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke
|
Phase 2 |